Myriad Genetics Expands Precise MRD Test to Colorectal, Renal and Breast Cancers
Event summary
- Myriad Genetics expanded its Precise MRD test to colorectal, renal, and breast cancers, targeting 6 million U.S. patients.
- The test uses whole-genome sequencing to track up to 1,000 patient-specific variants for ultrasensitive ctDNA detection.
- A new MONITOR-Breast study published in Future Oncology demonstrated high baseline detection rates (93%) and strong predictive value for treatment response.
- Precise MRD is designed for use across the cancer care continuum, from neoadjuvant therapy to long-term surveillance.
The big picture
Myriad Genetics' expansion of Precise MRD into three major cancer types underscores the shift toward personalized, data-driven oncology care. The test's ability to provide longitudinal insights and ultrasensitive detection positions it as a key tool in managing cancer treatment and surveillance. This move aligns with broader industry trends toward earlier disease detection and more precise treatment strategies.
What we're watching
- Clinical Adoption
- How quickly healthcare providers integrate Precise MRD into oncology workflows across academic and community settings.
- Market Expansion
- The pace at which Myriad Genetics expands the test to additional tumor types beyond breast, colorectal, and renal cancers.
- Competitive Positioning
- Whether Myriad can sustain its leadership in precision oncology diagnostics amid growing competition in molecular testing.
Related topics